MedTrace Logo

Endostar/PD-1 Inhibitors Combined With PP for Advanced NSCLC

NCT04063449 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 170

Last updated 2019-08-21

No results posted yet for this study

Summary

A Controlled Clinical Study of Endostar/PD-1 Inhibitors Combined With chemotherapy(Carboplatin-Pemetrexed) as First-line Treatment for Advanced Non-squamous Cell Lung Cancer With Negative Driving Gene

Conditions

  • Non-squamous Non-small Cell Lung Cancer

Interventions

DRUG

endostar/PD-1 inhibitor

Antiangiogenic therapy plus immunotherapy and chemotherapy

DRUG

endostar

Antiangiogenic therapy plus chemotherapy

Sponsors & Collaborators

  • Dong Wang

    lead OTHER

Principal Investigators

  • Dong Wang, PH.D · Daping Hospital, Third Military Medical University, Chongqing,China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-20
Primary Completion
2020-06-30
Completion
2021-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04063449 on ClinicalTrials.gov